458 related articles for article (PubMed ID: 24699062)
1. Ketamine infusions for treatment resistant depression: a series of 28 patients treated weekly or twice weekly in an ECT clinic.
Diamond PR; Farmery AD; Atkinson S; Haldar J; Williams N; Cowen PJ; Geddes JR; McShane R
J Psychopharmacol; 2014 Jun; 28(6):536-44. PubMed ID: 24699062
[TBL] [Abstract][Full Text] [Related]
2. Augmentation of response and remission to serial intravenous subanesthetic ketamine in treatment resistant depression.
Shiroma PR; Johns B; Kuskowski M; Wels J; Thuras P; Albott CS; Lim KO
J Affect Disord; 2014 Feb; 155():123-9. PubMed ID: 24268616
[TBL] [Abstract][Full Text] [Related]
3. Metabolic Syndrome Rather Than Body Mass Index Is Associated With Treatment Response to Ketamine Infusions.
Dale RM; Bryant KA; Thompson NR
J Clin Psychopharmacol; 2020; 40(1):75-79. PubMed ID: 31834094
[TBL] [Abstract][Full Text] [Related]
4. Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression.
Murrough JW; Perez AM; Pillemer S; Stern J; Parides MK; aan het Rot M; Collins KA; Mathew SJ; Charney DS; Iosifescu DV
Biol Psychiatry; 2013 Aug; 74(4):250-6. PubMed ID: 22840761
[TBL] [Abstract][Full Text] [Related]
5. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT.
Allen AP; Naughton M; Dowling J; Walsh A; Ismail F; Shorten G; Scott L; McLoughlin DM; Cryan JF; Dinan TG; Clarke G
J Affect Disord; 2015 Nov; 186():306-11. PubMed ID: 26275358
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.
Zhou Y; Zheng W; Liu W; Wang C; Zhan Y; Li H; Chen L; Li M; Ning Y
J Psychopharmacol; 2018 Oct; 32(10):1118-1126. PubMed ID: 30260273
[TBL] [Abstract][Full Text] [Related]
7. Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation.
Cusin C; Ionescu DF; Pavone KJ; Akeju O; Cassano P; Taylor N; Eikermann M; Durham K; Swee MB; Chang T; Dording C; Soskin D; Kelley J; Mischoulon D; Brown EN; Fava M
Aust N Z J Psychiatry; 2017 Jan; 51(1):55-64. PubMed ID: 26893373
[TBL] [Abstract][Full Text] [Related]
8. Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.
Anand A; Mathew SJ; Sanacora G; Murrough JW; Goes FS; Altinay M; Aloysi AS; Asghar-Ali AA; Barnett BS; Chang LC; Collins KA; Costi S; Iqbal S; Jha MK; Krishnan K; Malone DA; Nikayin S; Nissen SE; Ostroff RB; Reti IM; Wilkinson ST; Wolski K; Hu B
N Engl J Med; 2023 Jun; 388(25):2315-2325. PubMed ID: 37224232
[TBL] [Abstract][Full Text] [Related]
9. Cognitive function of patients with treatment-resistant depression after a single low dose of ketamine infusion.
Chen MH; Li CT; Lin WC; Hong CJ; Tu PC; Bai YM; Cheng CM; Su TP
J Affect Disord; 2018 Dec; 241():1-7. PubMed ID: 30081380
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of low-dose ketamine infusion in anxious vs nonanxious depression: revisiting the Adjunctive Ketamine Study of Taiwanese Patients with Treatment-Resistant Depression.
Chen MH; Lin WC; Wu HJ; Bai YM; Li CT; Tsai SJ; Hong CJ; Tu PC; Cheng CM; Su TP
CNS Spectr; 2021 Aug; 26(4):362-367. PubMed ID: 32419678
[TBL] [Abstract][Full Text] [Related]
11. [Effectiveness of ketamine in depressed patients resistant to ECT or rTMS therapy].
Gosek P; Chojnacka M; Bieńkowski P; Swiecicki Ł
Psychiatr Pol; 2014; 48(1):49-58. PubMed ID: 24946434
[TBL] [Abstract][Full Text] [Related]
12. Ketamine plus propofol-electroconvulsive therapy (ECT) transiently improves the antidepressant effects and the associated brain functional alterations in patients with propofol-ECT-resistant depression.
Zhang J; Tian H; Li J; Ji S; Chen S; Zhu J; Jiang D; Wang L; Li G; Chen M; Wang W; Lin X; Zhuo C
Psychiatry Res; 2020 May; 287():112907. PubMed ID: 32179210
[TBL] [Abstract][Full Text] [Related]
13. ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol.
Mathew SJ; Wilkinson ST; Altinay M; Asghar-Ali A; Chang LC; Collins KA; Dale RM; Hu B; Krishnan K; Kellner CH; Malone DA; Murrough JW; Ostroff RB; Sanacora G; Shao M; Anand A
Contemp Clin Trials; 2019 Feb; 77():19-26. PubMed ID: 30572160
[TBL] [Abstract][Full Text] [Related]
14. Effect of Ketamine on Rumination in Treatment-Resistant Depressive Patients.
Vidal S; Jermann F; Aubry JM; Richard-Lepouriel H; Kosel M
J Clin Psychopharmacol; 2020; 40(6):607-610. PubMed ID: 33044358
[TBL] [Abstract][Full Text] [Related]
15. Ketamine and Monoamine Oxidase Inhibitor Combination: Utility, Safety, Efficacy?
Bottemanne H; Bonnard E; Claret A; Petit AC; Gaillard R; Fossati P
J Clin Psychopharmacol; 2020; 40(6):636-638. PubMed ID: 33009225
[No Abstract] [Full Text] [Related]
16. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression.
Phillips JL; Norris S; Talbot J; Hatchard T; Ortiz A; Birmingham M; Owoeye O; Batten LA; Blier P
Neuropsychopharmacology; 2020 Mar; 45(4):606-612. PubMed ID: 31759333
[TBL] [Abstract][Full Text] [Related]
17. Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT).
Ekstrand J; Fattah C; Persson M; Cheng T; Nordanskog P; Åkeson J; Tingström A; Lindström MB; Nordenskjöld A; Movahed Rad P
Int J Neuropsychopharmacol; 2022 May; 25(5):339-349. PubMed ID: 35020871
[TBL] [Abstract][Full Text] [Related]
18. Early symptomatic improvements as a predictor of response to repeated-dose intravenous ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O; McIntyre RS; Rodrigues NB; Kaster TS; Cha DS; Brietzke E; Gill H; Nasri F; Lin K; Subramaniapillai M; Kratiuk K; Teopiz K; Lui LMW; Lee Y; Ho R; Shekotikhina M; Mansur RB; Rosenblat JD
Prog Neuropsychopharmacol Biol Psychiatry; 2021 Mar; 105():110126. PubMed ID: 33031861
[TBL] [Abstract][Full Text] [Related]
19. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Fava M; Freeman MP; Flynn M; Judge H; Hoeppner BB; Cusin C; Ionescu DF; Mathew SJ; Chang LC; Iosifescu DV; Murrough J; Debattista C; Schatzberg AF; Trivedi MH; Jha MK; Sanacora G; Wilkinson ST; Papakostas GI
Mol Psychiatry; 2020 Jul; 25(7):1592-1603. PubMed ID: 30283029
[TBL] [Abstract][Full Text] [Related]
20. A 12-month naturalistic observation of three patients receiving repeat intravenous ketamine infusions for their treatment-resistant depression.
Szymkowicz SM; Finnegan N; Dale RM
J Affect Disord; 2013 May; 147(1-3):416-20. PubMed ID: 23182590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
